The Clinical Features and Prognosis of Gastric Remnant Carcinoma after Treatment

Table 3

Clinicopathological features of the 12 patients with gastric remnant carcinoma who survived for less than a year.

No.	Gender	Age (years)	Interval (months)	TNM staging	Anastomotic site^†	Comorbidity	Previous surgery	Prognosis (months)
1	M	73	35	T1N3M0		HCC	Billroth II	6
2	M	55	28	T1N0M1	+	Liver metastasis	Billroth II	10
3	M	80	55	T1N0M1	+	Intestinal metastasis	Billroth II	5
4	M	50	20	T1N1M0	+	LN metastasis	Billroth II	11
5	M	48	15	T1N1M1	+	Liver and LN metastases	Billroth II	4
6	F	60	30	T1N0M2	−	Pulmonary and cervical metastases	Billroth II	3
7	M	83	42	T1N0M0	+	Uremia on dialysis and hypertension	Billroth II	1
8	F	68	43	T1N1M0	−	LN metastasis (bypass)	Billroth II	2
9	M	77	16	T1N1M0	−	CVA and hypertension	Billroth II	11
10	M	58	30	T1N2M0	+	LN metastasis (palliative gastrectomy)	Billroth II	8
11	F	70	30	T1N1M0	+	LN metastasis	Billroth I	3
12	M	85	30	T1N1M0	+	AMI and LN metastasis	Billroth II	11

^†Abbreviations: TNM: tumor-lymph node-metastasis; HCC: hepatocellular carcinoma; LN: lymph node; CVA: cerebrovascular accident; AMI: acute myocardial infarction.